Healthcare

Creso Pharma Limited (ASX:CPH)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Pharmaceuticals

Market Price : AUD 0.110 (0%)

(as on 2021-10-23 05:55:23)

Market Cap : AUD 132.172 M

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
0.11 0.11 0.11 0.11L 0.115 H 0.024L 0.47 H
Last Trade 0.11
Change% 0.0000
52 W H/L 0.47/0.024
EBITDA -25.498 M
NPAT After Abnormal Items -30.78 M
Equity 13.652 M
ROE% -179.12%
Total Liabilities 5.468 M
Total Revenue 2.642 M
Cash and Cash Equivalents 6.047 M

Stock Information

Share price 0.11
Market Cap 132.172 M
Price/Gross Cash Flow -15.80
Dividend Yield Excluding Special 0.00%
Ending Shares 902.296 M
52-Week Range 0.024-0.47
P/E ratio 0.000
Sector P/E --
EPS -8.30
EV/EBITDA --
Net Profit Margin (%) -999.04%
Gross Cash Flows Per Share -0.03
Net Gearing -20.45%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.01
Sales Per Share 0.01
Book Value Per Share 0.02

Announcements

Heading Date/Time
Mernova Completes THC Content Testing on New Strains  11/10/2021 9:11AM
Halucenex Update  06/10/2021 9:42AM
Mernova Secures over A$800,000 in New Purchase Orders  05/10/2021 10:04AM
Pause in Trading  05/10/2021 10:01AM
Halucenex Secures Research Agreement with Acadia University  20/09/2021 11:05AM
Pause in Trading  20/09/2021 9:50AM
Creso Pharma Launches New E-commerce Channels  17/09/2021 9:43AM
Secondary Trading Notice  13/09/2021 6:03PM
Creso Secures New Purchase Orders for Human Health Products  13/09/2021 9:26AM
Investor Presentation  09/09/2021 8:50AM
Notification regarding unquoted securities - CPH  06/09/2021 2:37PM
Proposed issue of securities - CPH  06/09/2021 2:28PM
Application for quotation of securities - CPH  06/09/2021 2:25PM
Creso Pharma Strengthens Management & Executive Team  06/09/2021 9:12AM
Half Yearly Report and Accounts  31/08/2021 5:37PM
Notification regarding unquoted securities - CPH  31/08/2021 9:56AM
NASDAQ Listing & RLH Merger Update  31/08/2021 9:29AM
Notification of cessation of securities - CPH  23/08/2021 4:48PM
Halucenex Commissions Extraction Unit  23/08/2021 9:38AM
Halucenex Awarded Dealer's License from Health Canada  16/08/2021 9:31AM
Trading Halt  12/08/2021 10:03AM
Pause in Trading  12/08/2021 9:53AM
Mernova secures medicinal cannabis sales licence & new POs  11/08/2021 9:51AM
Halucenex Continues to Make Progress ahead of Clinical Trial  04/08/2021 9:45AM
Quarterly Update & Appendix 4C  02/08/2021 8:22AM
Exercise of Options  30/07/2021 7:04PM
Application for quotation of securities - CPH  30/07/2021 6:36PM
Notification of cessation of securities - CPH  30/07/2021 6:20PM
Mernova to Introduce Fourteen New Strains  30/07/2021 9:29AM

Similar Companies

Related Articles

Load More

About Company

Creso Pharma Limited (ASX:CPH) brings its pharmaceutical skills and knowledge to the cannabis sector and strives for the highest quality in its products. The Company’s cannabis and hemp-derived products include therapeutic, nutraceutical, as well as lifestyle products.

Creso is providing pharmaceutical expertise with the delivery of the highest quality cannabis-based products. In this context, therapeutic-grade nutraceuticals derived from hemp are additional products the cannabis firm has been working on.

The Company uses Good Manufacturing Practice (GMP) standards to develop and manufacture its products with initial product registrations in Switzerland. The Company has global rights for several unique and proprietary pioneering delivery technologies that improve the bioavailability and absorption of cannabinoids.

Source: CPH Website

The group focuses on expanding its presence in the international markets and aims to offer a diverse product portfolio worldwide. The products developed by Creso are categorised into four categories - therapeutics, animal health, nutraceuticals, topicals and lifestyle.

  • Creso’s Therapeutics range is designed for the treatment of medical indications under the physician’s supervision.
  • The Nutraceutical products range aims to help in lowering stress and pain while supporting the natural health balance and wellbeing of individuals. cannaQIX® is the first and distinctive standardised nutraceutical product of the Company.
  • Creso Animal Health products are developed for animal health and wellbeing. Creso’s first of many animal products, anibidiol® is available via Veterinarians across Europe.
  • Creso’s Topical and Skin Care product range is meant to support skin health and improve the appearance of skin.

Creso Pharma’s products are based on cannabis and hemp grown with the GAP (Good Agricultural Practices) while being manufactured as per the highest quality standards by using GMP facilities where appropriate.

With the proposed acquisition of Canada-based Halucenex Inc., Creso Pharma is all set to enter the psychedelic space and will become the first ASX-listed wholly-owned psychedelic medicines company.

Corporate Information

company address Suite 5 CPC, 145 Stirling Highway, NEDLANDS, WA, AUSTRALIA, 6009

company phone08 9389 3180

company email[email protected]

company websitehttp://www.cresopharma.com

Dividends

Ex-Dividend Date Franking DPS (AUD) Dividend Yield
30/12/2020 -- 0.000 0.00%
30/12/2019 -- 0.000 0.00%
30/12/2018 -- 0.000 0.00%
30/12/2017 -- 0.000 0.00%
30/12/2016 -- 0.000 0.00%

Event Calendar

Event Type Event Date Event Year
Report (Interim) 2022-08-30 2022
Report (Annual) 2022-03-08 2022
Report (Prelim) 2022-02-28 2022

Financials

Breakdown 30/12/2020 30/12/2019 30/12/2018 30/12/2017 30/12/2016
Trading Revenue 2.448 M 3.626 M 558,382 243,798 8,022
Other Revenue 194,728 861,640 82,797 0 0
Total Revenue 2.642 M 4.488 M 641,179 243,798 8,022
Interest Income 317 57,093 144,037 98,453 6,498
Interest Expenses -9.269 M -2.09 M -432,216 0 -36,751
Expenses -17.476 M -14.352 M -15.284 M -15.412 M -4.216 M
EBITDA -14.833 M -9.864 M -14.643 M -15.168 M -4.208 M
Depreciation and Amortization -352,429 -401,667 -38,721 -6,638 -1,318
Depreciation -6,874 -138,235 -38,721 -6,638 -1,318
Amortisation -345,555 -263,432 0 0 0
EBIT -15.186 M -10.266 M -14.682 M -15.175 M -4.209 M
Pre Tax Profit -24.454 M -12.299 M -14.97 M -15.076 M -4.24 M
Tax Expense 0 0 0 0 0
Net Profit After Tax -24.454 M -12.299 M -14.97 M -15.076 M -4.24 M
Minority Interest 0 285,391 89,650 0 0
Preference Dividend 0 0 0 0 0
Net Abnormal Items -6.325 M -3.041 M -1.876 M 0 -344,705
Reported Net Profit After Abnormal Items -30.78 M -15.054 M -16.756 M -15.076 M -4.584 M
Ending Shares 902.296 M 174.117 M 124.188 M 109.506 M 57.725 M
Weighted Average Shares 370.625 M 143.784 M 112.552 M 83.143 M 31.79 M
EPS After Abnormal Items (cents) -8.3 -10.47 -14.89 -18.13 -14.42
Breakdown 30/12/2020 30/12/2019 30/12/2018 30/12/2017 30/12/2016
Total Current Assets 7.936 M 6.915 M 8.281 M 14.596 M 3.75 M
Total Non Current Assets 11.185 M 15.748 M 14.002 M 7 M 17,474
Total Assets 19.121 M 22.664 M 22.282 M 21.596 M 3.768 M
Total Current Liabilities 5.468 M 5.39 M 5.778 M 567,270 528,022
Total Non Current Liabilities 0 0 0 0 0
Total Liabilities 5.468 M 5.39 M 5.778 M 567,270 528,022
Net Assets 13.652 M 17.274 M 16.504 M 21.029 M 3.24 M
Breakdown 30/12/2020 30/12/2019 30/12/2018 30/12/2017 30/12/2016
Net Operating Cash -9.622 M -10.167 M -8.173 M -7.538 M -2.565 M
Net Invested Cash -831,689 -3.342 M -4.139 M -6.048 M 20,659
Net Financing Cash Flows 13.65 M 10.044 M 6.231 M 22.965 M 5.591 M
Beginning Cash 2.8 M 6.391 M 12.425 M 3.046 M 1
End Cash Position 6.047 M 2.8 M 6.391 M 12.425 M 3.046 M
Exchange Rate Adjustments 50,139 -124,670 46,463 0 0
Other Cash Adjustments 0 0 0 0 0
Ending Cash 6.047 M 2.8 M 6.391 M 12.425 M 3.046 M

© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK